Birth Control for Men: Why the Wait?

Quaziefoto/<a href="http://www.flickr.com/photos/quazie/780895252/sizes/l/in/photostream/">Flickr</a>

Facts matter: Sign up for the free Mother Jones Daily newsletter. Support our nonprofit reporting. Subscribe to our print magazine.


As Father’s Day approaches, I can’t help but think of contraception. Nearly every year I read an article promising that a male hormonal contraceptive is “just around the corner!”. Yeah, right. At least, in the US.

There actually IS a male contraceptive implant similar to Norplant, which was 100% effective in preventing pregnancies among its human trial subjects. But the companies that produced it, Schering and Organon, stopped investigating male contraceptives after Schering was bought by Bayer. There’s another contraceptive on the horizon though: RISUG. RISUG, which stands for Reversible Inhibition of Sperm Under Guidance, is a one-time injection directly into the vas deferens. The injection coats the inside of the vas with a polymer that breaks the sperms’ tails and ruptures their cells, making them incapable of fertilization. In effect, it’s a vasectomy without the surgery. RISUG is being tested in India, and so far, patients report is is 100% effective in preventing pregnancy and there are no adverse effects. Also, since it’s a one-time procedure, there’s no pills to remember to take, or condoms to break, so it’s more reliable than other forms of birth control. And if a man decides later he wants to have a child, the procedure is (theoretically) reversible with an injection of a substance that breaks down the polymer, though this has not been tested in humans yet.

So does that mean it’ll someday be offered in the US? Well, maybe. The problem in the US is two-fold. Firstly, pharmaceutical companies are not pushing on research to make solutions like RISUG available in the US. This means that most of the R&D funds are coming from the National Institute of Health. Secondly, there’s a perception that men don’t actually want to shoulder more of the responsibility for family planning because the benefits to them are not as pronounced as they are to women. This is undoubtedly one of the things hindering private investment. Douglas Colvard, a program director at a reproductive health non-profit, told Scientific American that at the end of the day, it’s not men who are going to get pregnant. A man can still walk away from a pregnancy. And for that reason, a successful male contraceptive might have to offer benefits other than birth control, such as reduced hair loss or increased metabolism.

A male pill might have to be easier on the body than female contraceptives, too. Women have long complained of weight gain, moodiness, and other birth control side-effects, but despite that, 62% of US women of reproductive age use contraceptives. A recent clinical trial for a male contraceptive delivered via injection (similar to Depo-Provera for women) was ended early despite promising early results due to participants’ complaints about side-effects such as depression, increased libido, and mood changes.

Diana Blithe, a program director at the National Institute for Child Health and Human Development, says that “The reality is we could get a product out there very quickly if companies would aggressively take on the process of making it happen,” she said. But until consumers really ask for that product, or until marketing studies show it would really sell, US companies really have little to gain by developing a male contraceptive. Since condoms are widely available, protect against STDs, and have very few if any side-effects, it may be a long wait.

 

 

REAL QUICK, REAL URGENT

Minority rule, corruption, disinformation, attacks on those who dare tell the truth: There is a direct line from what's happening in Russia and Ukraine to what's happening here at home. And that's what MoJo's Monika Bauerlein writes about in "Their Fight Is Our Fight" to unpack the information war we find ourselves in and share a few examples to show why the power of independent, reader-supported journalism is such a threat to authoritarians.

Corrupt leaders the world over can (and will) try to shut down the truth, but when the truth has millions of people on its side, you can't keep it down for good. And there's no more powerful or urgent argument for your support of Mother Jones' journalism right now than that. We need to raise about $450,000 to hit our online fundraising budget in these next few months, so please read more from Monika and pitch in if you can.

payment methods

REAL QUICK, REAL URGENT

Minority rule, corruption, disinformation, attacks on those who dare tell the truth: There is a direct line from what's happening in Russia and Ukraine to what's happening here at home. And that's what MoJo's Monika Bauerlein writes about in "Their Fight Is Our Fight" to unpack the information war we find ourselves in and share a few examples to show why the power of independent, reader-supported journalism is such a threat to authoritarians.

Corrupt leaders the world over can (and will) try to shut down the truth, but when the truth has millions of people on its side, you can't keep it down for good. And there's no more powerful or urgent argument for your support of Mother Jones' journalism right now than that. We need to raise about $450,000 to hit our online fundraising budget in these next few months, so please read more from Monika and pitch in if you can.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate